How to buy Cocrystal Pharma stock

Cocrystal Pharma, Inc is a biotechnology business based in the US. Cocrystal Pharma shares (COCP) are listed on the NASDAQ and all prices are listed in US Dollars. Cocrystal Pharma employs 13 staff and has a trailing 12-month revenue of around 0.00.

Cocrystal Pharma share price

Use our graph to track the performance of COCP stocks over time.

Cocrystal Pharma shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$0.76 - $2.48
50-day moving average	$1.38
200-day moving average	$1.43
Wall St. target price	$4.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.47

Buy Cocrystal Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cocrystal Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cocrystal Pharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cocrystal Pharma financials

Revenue TTM	$2 million
Gross profit TTM	$-4,293,000
Return on assets TTM	-14.48%
Return on equity TTM	-24.67%
Profit margin	0%
Book value	$0.75
Market capitalisation	$87.2 million

TTM: trailing 12 months

Shorting Cocrystal Pharma shares

There are currently 2.1 million Cocrystal Pharma shares held short by investors – that's known as Cocrystal Pharma's "short interest". This figure is 5.1% up from 2.0 million last month.

There are a few different ways that this level of interest in shorting Cocrystal Pharma shares can be evaluated.

Cocrystal Pharma's "short interest ratio" (SIR)

Cocrystal Pharma's "short interest ratio" (SIR) is the quantity of Cocrystal Pharma shares currently shorted divided by the average quantity of Cocrystal Pharma shares traded daily (recently around 1.2 million). Cocrystal Pharma's SIR currently stands at 1.77. In other words for every 100,000 Cocrystal Pharma shares traded daily on the market, roughly 1770 shares are currently held short.

However Cocrystal Pharma's short interest can also be evaluated against the total number of Cocrystal Pharma shares, or, against the total number of tradable Cocrystal Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cocrystal Pharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Cocrystal Pharma shares in existence, roughly 30 shares are currently held short) or 0.0378% of the tradable shares (for every 100,000 tradable Cocrystal Pharma shares, roughly 38 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cocrystal Pharma.

Find out more about how you can short Cocrystal Pharma stock.

Cocrystal Pharma share dividends

We're not expecting Cocrystal Pharma to pay a dividend over the next 12 months.

Have Cocrystal Pharma's shares ever split?

Cocrystal Pharma's shares were split on a 1:30 basis on 23 January 2018. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cocrystal Pharma shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Cocrystal Pharma shares which in turn could have impacted Cocrystal Pharma's share price.

Cocrystal Pharma share price volatility

Over the last 12 months, Cocrystal Pharma's shares have ranged in value from as little as $0.76 up to $2.48. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cocrystal Pharma's is 0.8114. This would suggest that Cocrystal Pharma's shares are less volatile than average (for this exchange).

Cocrystal Pharma overview

Cocrystal Pharma, Inc. , a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp.

Frequently asked questions

• What percentage of Cocrystal Pharma is owned by insiders or institutions?

  Currently 27.862% of Cocrystal Pharma shares are held by insiders and 14.232% by institutions.

• How many people work for Cocrystal Pharma?

  Latest data suggests 13 work at Cocrystal Pharma.

• When does the fiscal year end for Cocrystal Pharma?

  Cocrystal Pharma's fiscal year ends in December.

• Where is Cocrystal Pharma based?

  Cocrystal Pharma's address is: 19805 North Creek Parkway, Bothell, WA, United States, 98011

• What is Cocrystal Pharma's ISIN number?

  Cocrystal Pharma's international securities identification number is: US19188J3005

• What is Cocrystal Pharma's CUSIP number?

  Cocrystal Pharma's Committee on Uniform Securities Identification Procedures number is: 09072E103